At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

The medicine, lenacapavir, made by Gilead Sciences, has caused a stir because clinical trial data showed a single set of injections every six months could provide virtually complete protection ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

The findings of the two studies were so promising that Pepfar and the Global Fund for Aids, TB and Malaria announced in ...